Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback